Iñigo M. D.
- Country
- Spain
- Department
- Oncology
Research Overview
- Efficacy and Safety of PF-08634404 and Combination Therapy Versus Bevacizumab and Combination Therapy in Treatment-Naïve Participants With Metastatic Colorectal Cancer
- Randomized Phase 3 Study of Precemtabart Tocentecan With or Without Bevacizumab Versus Trifluridine/Tipiracil + Bevacizumab in Treated Metastatic Colorectal Cancer
- Phase 3 Randomized Study of Perioperative Dostarlimab vs. Standard of Care in Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Data & Insights
Has run more than one trial at 68 of 179 partner sites.
Specializations
Colorectal Cancer Specialization
This investigator focuses on advanced therapeutic approaches for colorectal cancer, with particular emphasis on stage II and stage III colon cancer treatments.
- High-risk colorectal cancer management
- Neoadjuvant therapy approaches
- Perioperative treatment strategies
The investigator's work encompasses both MSS (microsatellite stable) and MSI-H (microsatellite instability-high) tumor types.
Immunotherapy Research
Specialized in investigating immunotherapeutic interventions for colon cancer, particularly focusing on dostarlimab-based treatments in various clinical contexts.
- Combination therapy protocols
- Novel immunotherapy applications
- Treatment response assessment
Research includes evaluation of immunotherapy efficacy in both MMR-proficient and MMR-deficient cancers.
Innovative Treatment Approaches
Focuses on developing personalized treatment strategies for colorectal cancer patients, including ctDNA-guided therapy decisions.
- Biomarker-driven treatment selection
- Post-resection surveillance strategies
- Risk-adapted therapeutic approaches
Explores the integration of molecular diagnostics with therapeutic decision-making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.